Cart
sales@molnova.com
ORM-15341
CAS No. 1297537-33-7
ORM-15341( —— )
Catalog No. M11200 CAS No. 1297537-33-7
The active main metabolite of ODM-201, a potent wt/mutant androgen receptor (AR) inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 65 | In Stock |
|
| 10MG | 110 | In Stock |
|
| 25MG | 178 | In Stock |
|
| 50MG | 286 | In Stock |
|
| 100MG | 429 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameORM-15341
-
NoteResearch use only, not for human use.
-
Brief DescriptionThe active main metabolite of ODM-201, a potent wt/mutant androgen receptor (AR) inhibitor.
-
DescriptionThe active main metabolite of ODM-201, a potent wt/mutant androgen receptor (AR) inhibitor; inhibits wtAR/AR(F876L) with IC50s of 25/51 nM respectively; suppresses androgen-induced cell proliferation more efficaciously than enzalutamide or ARN-509.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetAndrogen Receptor (AR)
-
RecptorAndrogen Receptor (AR)
-
Research AreaEndocrinology
-
Indication——
Chemical Information
-
CAS Number1297537-33-7
-
Formula Weight396.8303
-
Molecular FormulaC19H17ClN6O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 37 mg/mL
-
SMILESCC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=CC(=NN3)C(=O)C
-
Chemical Name1H-Pyrazole-3-carboxamide, 5-acetyl-N-[(1S)-2-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Moilanen AM, et al. Sci Rep. 2015 Jul 3;5:12007.
molnova catalog
related products
-
VPC 14449
VPC 14449 is a potent and selective androgen receptor DNA-binding domain (AR-DBD) inhibitor with IC50 of 0.34 uM.
-
LGD-2226
LGD-2226 (LGD2226) is an orally active, selective androgen receptor modulator (SARM) with binding Ki of 1 nM.
-
Atraric acid
Atraric acid derivatives as a new chemical lead structure for novel therapeutic compounds as AR antagonists.
